N Androulakis
Overview
Explore the profile of N Androulakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
600
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, et al.
Ann Oncol
. 2019 Jun;
30(8):1304-1310.
PMID: 31228203
Background: The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) aimed to investigate whether a 3 months (3M) of oxaliplatin/fluoropyrimidine-based adjuvant chemotherapy (CT) is non-inferior to the 6-month (6M) administration in...
2.
Alexandrakis M, Pappa C, Kokonozaki M, Boula A, Vyzoukaki R, Staphylaki D, et al.
Med Oncol
. 2015 Jan;
32(3):42.
PMID: 25631632
Angiogenesis is an important hallmark in multiple myeloma (MM) pathogenesis, with the participation of various versatile molecules. Interleukin-20 (IL-20) is a pro-inflammatory cytokine with diverse angiogenic properties. Our purpose was...
3.
Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, et al.
Br J Cancer
. 2012 Nov;
107(12):1932-7.
PMID: 23169296
Background: We conducted an open-label, pilot phase II trial to evaluate the efficacy and safety of FOLFOXIRI plus cetuximab as first-line treatment of patients with metastatic colorectal cancer (mCRC). Methods:...
4.
Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, et al.
Br J Cancer
. 2012 Jun;
106(12):1917-25.
PMID: 22669159
Background: To investigate the clinical relevance of CK-19mRNA-positive circulating tumour cells (CTCs) detected before the initiation of front-line treatment in patients with metastatic breast cancer (MBC). Methods: The presence of...
5.
Kotsakis A, Kouroussis C, Androulakis N, Agelaki S, Kalbakis K, Vamvakas L, et al.
Oncology
. 2007 Jul;
71(3-4):190-6.
PMID: 17641537
Purpose: A phase I study was conducted to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of the pegylated liposomal doxorubicin (PLD) and oxaliplatin combination in patients with...
6.
Bozionelou V, Vamvakas L, Pappas P, Agelaki S, Androulakis N, Kalykaki A, et al.
Br J Cancer
. 2007 Jun;
97(1):43-9.
PMID: 17551496
To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of pegylated liposomal doxorubicin (PLD), paclitaxel (PCX) and gemcitabine (GEM) combination administered biweekly in patients with advanced solid tumours....
7.
Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kourousis C, Mavroudis D, et al.
Dig Dis
. 2007 Mar;
25(1):100-5.
PMID: 17384515
Background: A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer. Patients And Methods:...
8.
Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kouroussis C, Mavroudis D, et al.
J BUON
. 2007 Mar;
10(1):47-52.
PMID: 17335131
Purpose: A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan (CPT-11), 5-fluorouracil/leucovorin (5-FU/LV) (AIO regimen) as salvage treatment in patients with metastatic colorectal cancer (MCC)....
9.
Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Agelaki S, et al.
Ann Oncol
. 2006 Nov;
18(2):305-10.
PMID: 17079693
Background: Cetuximab is an IgG1 monoclonal antibody targeting the epidermal growth factor receptor and is able to reverse the resistance to irinotecan in patients with metastatic colorectal cancer (mCRC). This...
10.
Boukovinas I, Androulakis N, Vamvakas L, Papakotoulas P, Ziras N, Polyzos A, et al.
Ann Oncol
. 2006 Sep;
17(11):1687-92.
PMID: 16968872
Background: The purpose of this study was to investigate the toxicity and efficacy of the sequential administration of gemcitabine (GMB) in combination with cisplatin (CDDP) followed by docetaxel (Taxotere) as...